Current and emerging antiglycaemic pharmacological therapies: The renal perspective

Nephrology

Volumn 16, Issue 5, 2011, Pages 468-475

  Sharif, Adnan ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

antiglycaemic agent; diabetes mellitus; kidney allograft; kidney disease

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; COLESEVELAM; COLESTILAN; COLESTYRAMINE; DAPAGLIFLOZIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; TROGLITAZONE; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE;

ABDOMINAL PAIN; ADD ON THERAPY; BLOATING; CONGESTIVE HEART FAILURE; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLATULENCE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; KIDNEY INJURY; LACTIC ACIDOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MEGALOBLASTIC ANEMIA; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR DISEASE; RETINOL DEFICIENCY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT PLANNING; URINARY TRACT INFECTION; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; WEIGHT GAIN;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959862459     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01466.x     Document Type: Review

References (55)

1. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2011; 34 (Suppl 1): S11-61.
2. Davidson JA, Wilkinson A,. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: An endocrinologist's view. Diabetes Care 2004; 27: 805-12. (Pubitemid 38280557)
3. Nathan DM, Buse JB, Davidson MB, et al,. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. Davidson J, Wilkinson A, Dantal J, et al,. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75 (10 Suppl): SS3-24.
5. Zhou G, Myers R, Li Y, et al,. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-74. (Pubitemid 32995375)
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA,. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-89.
7. Chan NN, Brain HP, Feher MD,. Metformin-associated lactic acidosis: A rare or very rare clinical entity? Diabet. Med. 1999; 16: 273-81.
8. Peters N, Jay N, Barraud D, et al,. Metformin-associated lactic acidosis in an intensive care unit. Crit. Care 2008; 12: R149.
9. Runge S, Mayerle J, Warnke C, et al,. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes. Metab. 2008; 10: 91-3. (Pubitemid 350302435)
10. Salpeter S, Greyber E, Pasternak G, Salpeter E,. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2006; (1): CD002967.
11. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M,. Metformin in patients with type 2 diabetes mellitus: Reconsideration of traditional contraindications. Eur. J. Intern. Med. 2002; 13: 428.
12. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH,. Evaluation of prescribing practices: Risk of lactic acidosis with metformin therapy. Arch. Intern. Med. 2002; 162: 434-7. (Pubitemid 34150645)
13. Shaw JS, Wilmot RL, Kilpatrick ES,. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet. Med. 2007; 24: 1160-63. (Pubitemid 47437878)
14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5. (Pubitemid 40813563)
15. Groop LC,. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54.
16. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR,. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-36. (Pubitemid 41079631)
17. Evans JM, Ogston SA, Emslie-Smith A, Morris AD,. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-36.
18. Hardman JG, Limbird LE, Gilman AG,. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill, 2006.
19. Kahn SE, Haffner SM, Heise MA, et al,. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006; 355: 2427-43. (Pubitemid 44903747)
20. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E,. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 2008; 19: 182-7.
21. Villanueva G, Baldwin D,. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005; 80: 1402-5. (Pubitemid 41803620)
22. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE,. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007; 298: 1180-88. (Pubitemid 47403104)
23. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-71. (Pubitemid 46919772)
24. Singh S, Loke YK, Furberg CD,. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007; 298: 1189-95. (Pubitemid 47403105)
25. Lago RM, Singh PP, Nesto RW,. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-36. (Pubitemid 47464583)
26. U.S. Food and Drug Administration. FDA Drug Safety Podcast: FDA significantly restricts access to the diabetes drug Avandia. [Cited 28 September 2010.] Available from URL
27. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. [Cited 23 September 2010.] Available from URL
28. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M,. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-94. (Pubitemid 37430502)
29. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S,. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007; (2): CD004654.
30. Turk T, Pietruck F, Dolff S, et al,. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am. J. Transplant. 2006; 6: 842-6. (Pubitemid 43345023)
31. Drucker DJ,. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 2007; 117: 24-32. (Pubitemid 46048446)
32. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP,. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 2004; 428: 136-43. (Pubitemid 38891556)
33. Nauck MA, Duran S, Kim D, et al,. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 2007; 50: 259-67.
34. Zinman B, Hoogwerf BJ, Duran Garcia S, et al,. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann. Intern. Med. 2007; 146: 477-85. (Pubitemid 351650556)
35. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD,. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100. (Pubitemid 40616618)
36. Amori RE, Lau J, Pittas AG,. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
37. Weise WJ, Sivanandy MS, Block CA, Comi RJ,. Exenatide-associated ischemic renal failure. Diabetes Care 2009; 32: e22-3.
38. Bergman AJ, Cote J, Yi B, et al,. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-4. (Pubitemid 47036366)
39. Chan JC, Scott R, Arjona Ferreira JC, et al,. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 2008; 10: 545-55. (Pubitemid 351850898)
40. Scheen AJ,. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab. 2010; 12: 648-58.
41. Vincent SH, Reed JR, Bergman AJ, et al,. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab. Dispos. 2007; 35: 533-8. (Pubitemid 46513255)
42. Horvath K, Jeitler K, Berghold A, et al,. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007; (2): CD005613.
43. Jackson MA, Holland MR, Nicholas J, Lodwick R, Forster D, Macdonald IA,. Hemodialysis-induced hypoglycemia in diabetic patients. Clin. Nephrol. 2000; 54: 30-34. (Pubitemid 30456802)
44. LeRoith D, Roberts CT Jr,. The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195: 127-37. (Pubitemid 36588961)
45. Johnson JA, Gale EAM,. Diabetes, insulin use, and cancer risk: Are observational studies part of the solution-or part of the problem? Diabetes 2010; 59: 1129-31.
46. Mather A, Pollock C,. Renal glucose transporters: Novel targets for hyperglycemia management. Nat Rev Nephrol. 2010; 6: 307-11.
47. Mogensen CE,. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 1971; 28: 101-9.
48. Matschinsky FM,. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 2009; 8: 399-416.
49. Unger RH, Orci L,. Role of glucagon in diabetes. Arch. Intern. Med. 1977; 137: 482-91. (Pubitemid 9032901)
50. Petersen KF, Sullivan JT,. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-24. (Pubitemid 33124047)
51. Bays HE, Goldberg RB, Truitt KE, Jones MR,. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch. Intern. Med. 2008; 168: 1975-83.
52. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR,. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 1479-84.
53. Schmitz O, Brock B, Rungby J,. Amylin agonists: A novel approach in the treatment of diabetes. Diabetes 2004; 53 (Suppl 3): S233-8. (Pubitemid 39564549)
54. Riddle M, Frias J, Zhang B, et al,. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007; 30: 2794-9. (Pubitemid 350083120)
55. Ryan G, Briscoe TA, Jobe L,. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des. Devel. Ther. 2009; 2: 203-14.